by Communication Team | Aug 6, 2020 | ODYSSEY
Results from a sub-study of the ODYSSEY trial, published in The Lancet HIV journal, show that children over 20kg in weight can safely take adult doses (50mg) of the anti-HIV drug dolutegravir. With over half of children living with HIV globally weighing at over 20kg,...
by Communication Team | Jun 29, 2020 | ODYSSEY
Picturing Health have developed a short video explaining how dolutegravir (DTG), using preliminary data from the ODYSSEY trial, has gained approval for use in children. Picturing Health is a non-profit film producer with the aim to improve public health. Click here to...
by Communication Team | Jun 29, 2020 | ODYSSEY
Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. Food and Drug Administration (FDA) of the adult formulation for children weighing ≥20kg and dolutegravir (DTG) dispersible tablets...
by Communication Team | May 27, 2020 | ODYSSEY
New videos have been developed by Picturing Health, to inform and promote behaviour that can reduce the spread of Coronavirus in Africa and South Asia. Through knowledge and information Picturing Health is aiding communities to slow the epidemic and protect those most...
by Communication Team | May 21, 2020 | ODYSSEY
The COVID-19 pandemic is affecting people and health services around the world. Many of the healthcare professionals involved with the ODYSSEY trial have been providing care to patients with COVID-19 in hospitals, clinics and communities and dealing with the public...
by odysseyadmin | Feb 11, 2020 | ODYSSEY
Results from the ODYSSEY trial will be presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, USA. The trial team’s abstract titled “Adequate dolutegravir exposure dosed bid with rifampicin in children 6 to <18 years” has...
Recent Comments